Navigation Links
Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Date:1/5/2011

RICHMOND, Calif., Jan. 5, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 12:30 pm PT (3:30 pm ET) on Thursday, January 13, 2011 at the 29th Annual J.P. Morgan Healthcare Conference which will be held in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
4. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
5. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
6. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
7. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
9. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... ... April 26, 2016 , ... BaseHealth , the comprehensive ... company as Chief Business Officer. Arianpour, a genomics pioneer and visionary commercial leader ... most recently Chief Commercial Officer of Pathway Genomics. He has held senior executive ...
(Date:4/26/2016)... ... April 26, 2016 , ... ... systems, announces the latest technology innovation for its Volume Pattern Generator (VPG) line ... for production of advanced photomasks as well as a solution for mid volume ...
(Date:4/26/2016)... MA (PRWEB) , ... April 26, 2016 , ... This ... Town Scottsdale and will offer attendees an opportunity to get the lowdown on female ... , Over cocktails and appetizers, Dr. Jesse Hade, of Boston IVF - The Arizona ...
(Date:4/26/2016)... ... 26, 2016 , ... Seattle based non-profit, The Institute for ... Corporation. The grant will be used to further the scientific research goals of ... http://www.ivsci.org , In accounting the grant to the IVS, Mr. Glenn ...
Breaking Biology Technology:
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
(Date:3/18/2016)... March 18, 2016 --> ... Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter ... companies in the border security market and the continuing migration ... Europe has led visiongain to publish ... success. --> defence & security companies in ...
Breaking Biology News(10 mins):